Source:


Sands BE, et al. OP108. Estimated effects of screening delays due to SARS-CoV-2 pandemic on colorectal cancer mortality. Presented at: UEG Week; Oct. 11-13, 2020.

Disclosures: Sands received consultancy fees from 4D Pharma, Abbvie, Allergan Sales, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Capella Biosciences, Celgene, Eli Lilly and Company, EnGene, Ferring, Gilead, Janssen, Lyndra, MedImmune, Oppilan Pharma, Otsuka, Palatin Technologies, Pfizer, Progenity, Rheos Medicines, Seres Therapeutics, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, Vivelix Pharmaceuticals, WebMD, and research funding from Celgene, Janssen, Pfizer, and Takeda. Please see the abstract for all other authors’ relevant financial disclosures.
October 13, 2020
1 min read
Save

Mirikizumab demonstrates efficacy up to 52 weeks in Crohn’s disease

Source:


Sands BE, et al. OP108. Estimated effects of screening delays due to SARS-CoV-2 pandemic on colorectal cancer mortality. Presented at: UEG Week; Oct. 11-13, 2020.

Disclosures: Sands received consultancy fees from 4D Pharma, Abbvie, Allergan Sales, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Capella Biosciences, Celgene, Eli Lilly and Company, EnGene, Ferring, Gilead, Janssen, Lyndra, MedImmune, Oppilan Pharma, Otsuka, Palatin Technologies, Pfizer, Progenity, Rheos Medicines, Seres Therapeutics, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, Vivelix Pharmaceuticals, WebMD, and research funding from Celgene, Janssen, Pfizer, and Takeda. Please see the abstract for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 2 data support the safety and efficacy of mirikizumab in patients with Crohn’s disease, according to results presented at UEG Week.

“At UEG Week, Lilly presented the first disclosure of new 52-week efficacy and safety data from the phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active Crohn’s disease, and results showed continued symptom improvement and endoscopic response and remission,” Lotus Mallbris, MD, PhD, vice president and global head of immunology product development at Lilly, told Healio Gastroenterology. “These encouraging phase 2 results continue to provide evidence of the efficacy and safety of mirikizumab in [inflammatory bowel disease] indications, and we look forward to continuing our clinical program for mirikizumab and hope to help those living with Crohn’s disease.”

Phase 2 data support the safety and efficacy of mirikizumab in patients with Crohn’s disease.
Adobe Stock

Researchers randomly assigned patients with moderate-to-severe CD to placebo, 200 mg mirikizumab, 600 mg mirikizumab, 1,000 mg mirikizumab or administered IV every 4 weeks at 0, 4 and 8 weeks. At week 12, patients who received mirikizumab and achieved 1 point or more improvement in Endoscopic Score for Crohn’s Disease were additionally randomly assigned to continue IV treatment (n = 41) or subcutaneous 300 mg mirikizumab every 4 weeks (n = 46). Investigators assessed clinical and endoscopic endpoints at 52 weeks.

Results showed at 52 weeks, the endoscopic response rate was 58.5% in the IV group and 58.7% in the subcutaneous mirikizumab group. The patient-reported remission rate in the IV group was 46.3% and 66.7% in the subcutaneous group.

According to researchers, those in the IV group and subcutaneous group who had an endoscopic response at week 12 also had an endoscopic response at week 52 (69.6% and 66.7%, respectively). At 12 weeks, 50% of those in the IV group and 64.3% in the subcutaneous group who had endoscopic remission also had endoscopic remission at 52 weeks. Because of an adverse event, one patient from each group discontinued.